Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07103486 · ClinicalTrials.gov registry record
A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 264
- Enrollment target
NCT07103486 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 264 participants.
The verdict
NCT07103486 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 264 participants
- Enrollment target
Study Summary
The aim of this study was to evaluate the therapeutic benefit of tisagenlecleucel compared to the existing standard of care in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). For tisagenlecleucel patients, patient-level data from the JULIET study (CTL019C2201) was used. Data for patients treated with the appropriate comparator therapy (ACT) in German routine care was collected via chart review by 8 medical centers in Germany. The medical charts provided data on adult patients at the time of the qualifying treatments in the time period from approximately 2010 to 2017 with the longest possible follow-up phases (up to 5 years, but only until December 31, 2020).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2023-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07103486
The ClinicalTrials.gov registry entry for NCT07103486 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07103486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07103486 about?
NCT07103486 is a clinical study titled "A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma". The aim of this study was to evaluate the therapeutic benefit of tisagenlecleucel compared to the existing standard of care in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). For tisagenlecleucel patients, patient-level data from the JULIET study (CTL019C2201) w...
What is the current status of trial NCT07103486?
This trial is currently completed. The enrollment target is 264 participants. The study started on 2021-04-01. Estimated completion is 2023-01-31.
Who is sponsoring clinical trial NCT07103486?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.